Quality and Quantity: Dual Benefits of Ablative Radiation in Oligometastatic Pancreatic Cancer.

Oligometastatic pancreatic cancer (OPanc) poses significant opportunities in management, as increasingly metastases can be safely and effectively targeted with local therapy. We review the existing literature on SABR for OPanc, highlighting its potential benefits and limitations with an aim to define the trajectory of opportunity. SABR may offer a meaningful benefit to patients with OPanc, improving quality of life by enabling breaks from systemic therapy while potentially enhancing quantity of life or survival. Patient selection and clearly defined goals will be critical to demonstrate the value of this approach, and well powered prospective studies may be key. The most intriguing aspect of this discussion is the potential for SABR to enhance antitumor immunity that may play a role in prolonged minimal residual disease that can be achieved in some patients. This can translate to improved quality of life by reducing the need for systemic therapy. This approach may offer a novel solution to the treatment challenges associated with OPanc. Further research is needed to confirm the hypotheses and establish the definitive role of SABR in OPanc treatment.